Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives
Open accessThe DOI matches its Crossref record; 160 of the 161 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) and bromodomain-containing proteins (BCPs) play a key role in chromatin remodeling. Based on their ability to regulate inducible gene expression in the context of inflammation and cancer, HDACs and BCPs have been the focus of drug discovery efforts, and numerous small-molecule inhibitors have been developed. However, dose-limiting toxicities of the first generation of inhibitors, which typically target multiple HDACs or BCPs, have limited translation to the clinic. Over the last decade, an increasing effort has been dedicated to designing class-, isoform-, or domain-specific HDAC or BCP inhibitors, as well as developing strategies for cell-specific targeted drug delivery. Selective inhibition of the epigenetic modulators is helping to elucidate the functions of individual epigenetic proteins and has the potential to yield better and safer therapeutic strategies. In accordance with this idea, several in vitro and in vivo studies have reported the ability of more selective HDAC/BCP inhibitors to recapitulate the beneficial effects of pan-inhibitors with less unwanted adverse events. In this review, we summarize the most recent advances with these strategies, discussing advantages and limitations of these approaches as well as some therapeutic perspectives, focusing on autoimmune and inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Selective domain targeting of BD1 and BD2. (A) BET proteins family of BCPs comprise the ubiquitously expressed BRD2, BRD3, and BRD4 and BRDT, which all harbor two highly conserved tandem bromodomains, BD1 and BD2, allowing them to recognize acetylated lysine. (B) BD1 and BD2 have distinct functions. BD1 binding is sufficient to maintain homeostatic and oncogenic gene transcription programs, while BD2 binding is required to promote an inflammatory transcriptional response. (C) Domain-selective inhibitors for BD1 and BD2 show preferential effects on different types of cellular functions [141].](https://figures.cochat.ai/paper-figures/ce06f9e70a4c4ae0b0e25c87dfd3a566/selective-targeting-of-epigenetic-readers-and-histone-deacetylases-in-autoimmune-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These inhibitors are capable of specifically targeting categories, subtypes, and structural domains,491 potentially providing more pronounced benefits in terms of efficacy, safety, and tolerability.67”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [491]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Janczura, K. J., Volmar, C.-H., Sartor, G. C., Rao, S. J., Ricciardi, N. R., Lambert, G., Brothers, S. P., & Wahlestedt, C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805436115 · Cited by 183 · cited 1×
“Inhibitors with a high degree of reported selectivity toward HDAC3, including RGFP966, MI192, and ITF3100, have been shown to efficiently attenuate inflammatory responses [33,58,59,68] and to restore LPS tolerance in inflammatory macrophages in vitro [33].”
BackgroundRetractedRegulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., Lees, C. W., Balschun, T., Lee, J., Roberts, R., et al. (2010) · Nature Genetics · doi:10.1038/ng.717 · Cited by 2,520
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989 · cited 4×
“While achieving this is a challenge due to conserved structural similarity between HDAC isoforms [12], HDACi has been reported with selectivity for HDAC1, HDAC2, HDAC3 [33,58–61], HDAC8 [62,63], HDAC6 [64], HDAC11 [65], SIRT1, and SIRT2 [66,67].”
BackgroundInfluentialInflammation and wound healing: the role of the macrophage
Koh, T. J., & DiPietro, L. A. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411001943 · Cited by 1,667
Suppression of inflammation by a synthetic histone mimic
Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., et al. (2010) · Nature · doi:10.1038/nature09589 · Cited by 1,563
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
Targeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,243 · cited 2×
“The most extensively studied families of BCPs are BD and extra-terminal domain (BET) proteins, consisting of four individual proteins: BRD2, BRD3, BRD4, and BRDT [14].”
BackgroundMacrophage Polarization in Inflammatory Diseases
Liu, Y.-C., Zou, X.-B., Chai, Y.-F., & Yao, Y.-M. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8879 · Cited by 1,085
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Old age as a risk factor for liver diseases: Modern therapeutic approaches
Georgieva, M., Xenodochidis, C., & Krasteva, N. A. (2023) · Experimental Gerontology · doi:10.1016/j.exger.2023.112334 · Cited by 71
“Tefinostat targets epigenetic enzymes, such as histone deacetylases, and is being investigated as a potential treatment for various liver diseases, including MASLD and HCC (Ghiboub et al., 2021) (Tables 1 and 4).”
BackgroundImpact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections
Bhat, M. F., Srdanović, S., Sundberg, L.-R., Einarsdottir, H., Marjomäki, V., & Dekker, F. J. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104193 · Cited by 49
New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis
Luan, Y., Liu, H., Luan, Y., Yang, Y., Yang, J., & Ren, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.863677 · Cited by 34
“HDACi has been extensively studied in recent years and has been regarded to have a potential therapeutic effect on many diseases, including neurodegenerative diseases, autoimmune diseases, acute graft-versus-host disease, and so on (Vojinovic et al., 2011; Ghiboub et al., 2021).”
BackgroundKadier, K., Niu, T., Ding, B., Chen, B., Qi, X., Chen, D., Cheng, X., Fang, Y.-Z., Zhou, J., Zhao, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202309459 · Cited by 35
Traumatic brain injury-associated epigenetic changes and the risk for neurodegenerative diseases
Smolen, P. D., Dash, P. K., & Redell, J. B. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1259405 · Cited by 29
“HDAC inhibition may also decrease expression of pro-inflammatory factors in neurons and immune cells (Dai et al., 2021; Ghiboub et al., 2021).”
BackgroundGhiboub, M., Köster, J., Craggs, P. D., Yim, A. Y. F. L., Shillings, A., Hutchinson, S., Bingham, R. P., Gatfield, K. M., Hageman, I., Yao, G., et al. (2022) · BMC Biology · doi:10.1186/s12915-022-01380-6 · Cited by 28
“Readers are recruited to chromatin possessing specific epigenetic “marks” and regulate gene expression through mechanisms that modulate DNA accessibility to transcription factors (TFs) and the transcriptional machinery [19, 20].”
Self-citationBromodomain (BrD) Family Members as Regulators of Cancer Stemness—A Comprehensive Review
Czerwińska, P., & Mackiewicz, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020995 · Cited by 24
Gazzillo, E., Pierri, M., Colarusso, E., Chini, M. G., Ferraro, M. G., Piccolo, M., Irace, C., Bruno, I., Bifulco, G., Terracciano, S., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106677 · Cited by 17
BML-281 promotes neuronal differentiation by modulating Wnt/Ca2+ and Wnt/PCP signaling pathway
Choi, J., Gang, S., Ramalingam, M., Hwang, J., Jeong, H., Yoo, J., Cho, H., Kim, B. C., Jang, G., Jeong, H., et al. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04857-2 · Cited by 17
The association between bromodomain proteins and cancer stemness in different solid tumor types
Czerwińska, P., Jaworska, A. M., Wlodarczyk, N. A., Cisek, M., Karwacka, M., Lipowicz, J. M., Ostapowicz, J., Rosochowicz, M. A., & Mackiewicz, A. A. (2022) · International Journal of Cancer · doi:10.1002/ijc.33937 · Cited by 15
Hu, W., Shen, J., Zhou, C., Tai, Z., Zhu, Q., Chen, Z., Huang, Y., & Sheng, C. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01681 · Cited by 13
The regulatory mechanisms and treatment of HDAC6 in immune dysregulation diseases
Liang, Y., Wang, Y., Xing, J., Li, J., & Zhang, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1653588 · Cited by 11
Elfiky, A. M. I., Canñizares, J. L., Li, J., Yim, A. Y. F. L., Verhoeven, A. J., Ghiboub, M., & de Jonge, W. J. (2024) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiae137 · Cited by 9
Self-citationPersonalized Medicine in Autoimmune Diseases
Díaz‐Peña, R. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111181 · Cited by 9
Xu, Y., Yang, Q., Lu, H., Zhang, J., Xu, J., Liu, X., Wang, J., Xie, Z., & Li, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1825523 · Cited by 7
The role of HDAC6 in fibrosis: a novel and effective therapy strategy
Zheng, L., Zhu, X., Du, J., & Liu, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-02840-9 · Cited by 6
“HDAC6 has emerged as a promising therapeutic target for various conditions, including cancer, autoimmune and inflammatory diseases, and neuro-degenerative diseases [14–19].”
Epigenetic Therapies for Inflammatory and Immune-Mediated Skin Diseases
Makridou, A., Elemes, D. I., Liakou, M. E., Theotokis, P., Gargani, S., Vakirlis, E., Meditskou, S., Onoufriadis, A., Μanthou, M. E., & Dermitzakis, I. (2026) · Biomedicines · doi:10.3390/biomedicines14020373 · Cited by 6
“Pan-HDAC inhibitors broadly enhance H3 and H4 acetylation by preventing deacetylation, whereas selective inhibitors sustain elevated acetylation in an isoform, context, and substrate-specific manner, affecting chromatin and non-histone protein function [85–88].”
Ghiboub, M., Bell, M. J., Sinkevičiūtė, D., Prinjha, R. K., de Winther, M. P. J., Harker, N., Tough, D. F., & de Jonge, W. J. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45050269 · Cited by 4
“SP140 is an epigenetic reader protein harboring a bromodomain (Brd) [12,13]; Brd recognizes acetylated lysine residues on histone tails and regulates gene expression through mechanisms that modulate DNA accessibility to transcription factors (TFs) and the transcriptional machinery [14,15].”
BackgroundSelf-citationEpigenetic programming of macrophages across inflammatory and malignant diseases
Mohammad, S. I., Owida, H. A., Vasudevan, A., Ballal, S., Alshdaifat, N., Akberzeda, A., Singh, A., Kavitha, V., Maharana, L., & Sharma, M. K. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04758-9 · Cited by 2
The Role of Epigenetics in Autoimmune Disorders
Klein, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91909-8.00004-9 · Cited by 2
Zhu, C., Stolz, V., Simonovic, N., Al-Rubaye, O., Vcelkova, T., Moos, V., Hess, L., Hagelkrüys, A., Madern, M., Reiter, W., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.14.536700 · Cited by 3
“although no human clinical data are available yet for inflammatory and autoimmune diseases [25].”
BackgroundEpigenetic mechanisms in traumatic brain injury: a focus on astrocytes and therapeutic implications
Li, L., Bonfoey, A. M., Sun, B., Harris, O. A., & Luo, J. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03974-1 · Cited by 1
“…GFAP-promoter-driven vectors [167], nanoparticle carriers, and exosome-based systems [149– 151]—limit off-target effects, while isoform-selective inhibitors targeting discrete HDACs [58], DNMTs [168], or inflammatory transcriptional regulators provide complementary temporal control.”
Epigenetics and personalized medicine of brain cancer
Lambrou, G. Ι. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823008-4.00017-2
Han, B., Wang, H., Wu, X., Liu, Y., Shen, A., Yang, X., Wang, X., & Zhang, Q. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00612
Felten, R. (2023) · theses.fr (ABES) · doi:10.70675/d025ae83z5704z4d78z9695z98483d8b8adc
Bone-specific regulatory T cell mediators
Mishra, A. K., Singh, H., Agarwal, J., Pinki, K., Kumar, A., Mishra, A., & Khan, G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43846-2.00016-7
Ekwosi, C., Kasprzyk-Pawelec, A., Janczarek, M., & Masłyk, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167365
“…trichostatin A, a histone deacetylase (HDAC) inhibitor, designed to rectify epigenetic anomalies, have demonstrated potential in preclinical autoimmune models, their clinical applicability is highly limited by poor disease specificity [14], significant toxicity [15], as well as off-target effects.”
PATIL, D. P., Chavhan, D. P. J., & Malage, D. P. T. (2026) · International Journal of Versatile Research and Analysis · doi:10.56975/ijvra.v4i9.710746
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
Metadata
- Authors
- Ghiboub, M., Elfiky, A. M. I., de Winther, M. P. J., Harker, N. R., Tough, D. F., & de Jonge, W. J.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
- Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Centers, University of Amsterdam, 1105 BK Amsterdam, The Netherlands
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-04-23
- Volume
- 11
- Issue
- 5
- Pages
- 336
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8145108
- OpenAlex
- W3159535985
- Cited by
- 28
- References
- 161
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 5 · 2023: 7 · 2022: 4 · 2021: 2
- FWCI
- 0.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- European Commission (HORIZON2020, 641665)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- histone deacetylase, epigenetic reader protein, selective inhibitors, isoform-selective inhibitors, chromatin remodeling, autoimmune disease, inflammatory diseases, histone deacetylase inhibitors, bromodomain inhibitors, drug toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.